Overall verdict
Neutral
6.2/10
1-year performance
+28.96%
Score breakdown
Up 29.0% over 1 year, 97% of the 52-week range.
Strongest: Profitability 10.0/10. Weakest: Growth 3.4/10.
23 analysts, target -0.0% vs the price.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure ; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis ; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 ;
Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients ; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients ; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase ;
Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps ; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis ; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer ; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors ;
Zolgensma to treat genetic root cause of spinal muscular atrophy ; Lucentis ; Leqvio to reduce LDL cholesterol ; Lutathera ; Scemblix ; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol.
Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Six
Switzerland
CEO
Dr. Vasant Narasimhan M.D.
Founded
1996
Employees
75 267
Revenue / employee
758 983 USD
Next earnings
February 3, 2027
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
135.22 CHF
52-week low
99.45 CHF
1-year performance
28.96%
Rising
Year-to-date performance
22.22%
Rising
Drawdown
-0.74%
Near its high
Position in the 52-week range
97% of range
Range: 108.31 CHF - 118.09 CHF (2 methods agree)
The price implies growth of 4.83% per year; the company grows at 12.48%.
Quality and profitability
10.0/10Gross margin 74.3%, net margin 18.0%, ROIC 13.5%, ROE 24.0%.
Net margin
18.03%
Exceptional
Sector 9.96%|S&P 13.40%
Gross margin
74.31%
Exceptional
Return on equity (ROE)
23.98%
Exceptional
Sector 6.73%|S&P 17.06%
Return on invested capital (ROIC)
13.52%
Exceptional
Free cash flow margin (FCF)
27.99%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.55x
Exceptional
Margin stability
13.3 pts
Very uneven
Revenue to net income
Growth
3.4/10Revenue up 6.0% over 1 year, -0.2% a year over 5, EPS 12.5% a year over 5.
Revenue (trailing 12 months)
52.8Md USD
Revenue growth (1y)
5.98%
Solid
Revenue growth (3y)
12.35%
Moderate
EPS growth (1y)
-68.37%
Declining
EPS CAGR (5y)
12.48%
Exceptional
EPS revisions (3 months)
3.67%
Revised up
Valuation
4.9/10P/E 32.5x, forward P/E 24.2x, EV/EBITDA 15.7x, PEG 2.60. The multiple sits in the 74th percentile of its own 5-year history.
P/E (TTM)
32.5x
Fair
Sector 27.7x|S&P 23.6x
Forward P/E
24.2x
Expensive
EV / EBITDA
15.7x
Fair
Sector 14.2x|S&P 15.5x
PEG
2.60
Very expensive
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
113.20 CHF
Overvalued
P/E vs its own 5-year history
among the 26% highest valuations
Pricier than usual
Market cap
292Md USD
Financial strength
7.3/10Cash covers 18.6% of the debt, net debt/EBITDA 1.0x.
Net debt / EBITDA
1.0x
Solid
Gearing (net debt / equity)
104.71%
Stretched
Cash
9.0Md USD
Cash / market cap
3.07%
Tight
Cash / total debt
18.58%
Tight
Interest coverage
15.4x
Very solid
Net debt
39.3Md USD
Equity
37.5Md USD
Closed daily candles, 2 years
Last close on November 11, 2026: 132.74 CHF
- MM20130.09
- MM50122.94
- MM200122.15
- RSI 1462.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.40%
200-day average slope, 3 months
+4.41%
50-day average slope, 1 month
+1.31%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
1.22 % per day
Volatility change
-20.67%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 6.66 (12) | 9.10 (18) | 57 762 (19) | 23 722 (14) | 12 747 (14) |
| 2027 | 8.48 (12) | 10.03 (20) | 61 711 (20) | 25 603 (15) | 15 683 (14) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 503 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN | 7.1 | 7.0 | 286Md USD | 26.7x | 17.7 % | 7.1 % | 14.4 % | 1.2x | 3.6 % | 3.7 % | ||
| 2 | BMY | 6.6 | 6.9 | 129Md USD | 13.9x | 18.5 % | 7.0 % | 14.0 % | 1.9x | 7.2 % | 32.5 % | ||
| 3 | NOVN | 6.2 | 6.5 | 292Md USD | 32.5x | 18.0 % | 6.0 % | 13.5 % | 1.0x | 5.1 % | 29.0 % | ||
| 4 | NOVO B | 6.2 | 7.7 | 178Md USD | 10.7x | 33.9 % | 5.6 % | 38.1 % | 0.7x | 6.0 % | -8.5 % | ||
| 5 | ROP | 6.2 | 6.4 | 385Md USD | 26.2x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 4.7 % | 42.5 % | ||
| 6 | LLY | 6.0 | 5.1 | 1.4T USD | 47.2x | 31.9 % | 38.6 % | 36.3 % | 1.2x | 1.5 % | 48.7 % | ||
| 7 | JNJ | 5.6 | 5.2 | 675Md USD | 42.5x | 16.2 % | 5.9 % | 13.6 % | 0.9x | 3.1 % | 48.1 % | ||
| 8 | MRK | 5.4 | 3.6 | 363Md USD | 150.3x | 3.6 % | 5.5 % | 2.6 % | 1.2x | 4.1 % | 68.5 % | ||
| 9 | PFE | 5.2 | 4.6 | 168Md USD | 42.1x | 6.3 % | -0.4 % | 2.7 % | 2.3x | 7.0 % | 20.3 % |
